IZOTROPIC CORP. (1R3) - Total Assets
Based on the latest financial reports, IZOTROPIC CORP. (1R3) holds total assets worth €685.34K EUR (≈ $801.23K USD) as of January 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
IZOTROPIC CORP. - Total Assets Trend (2022–2025)
This chart illustrates how IZOTROPIC CORP.'s total assets have evolved over time, based on quarterly financial data. Also see how much is IZOTROPIC CORP. worth for the company's overall valuation and market capitalisation.
IZOTROPIC CORP. - Asset Composition Analysis
Current Asset Composition (April 2025)
IZOTROPIC CORP.'s total assets of €685.34K consist of 95.4% current assets and 4.6% non-current assets. Review how much debt does IZOTROPIC CORP. carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 66.1% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how IZOTROPIC CORP.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for IZOTROPIC CORP. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IZOTROPIC CORP.'s current assets represent 95.4% of total assets in 2025, a decrease from 99.2% in 2022.
- Cash Position: Cash and equivalents constituted 66.1% of total assets in 2025, down from 81.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
IZOTROPIC CORP. Competitors by Total Assets
Key competitors of IZOTROPIC CORP. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$1.38 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$584.37K |
IZOTROPIC CORP. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.09 | 0.07 | 0.05 |
| Quick Ratio | 0.09 | 0.07 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-5.40 Million | €-4.81 Million | €-4.33 Million |
IZOTROPIC CORP. - Advanced Valuation Insights
This section examines the relationship between IZOTROPIC CORP.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 99.59 |
| Latest Market Cap to Assets Ratio | 21.39 |
| Asset Growth Rate (YoY) | 78.5% |
| Total Assets | €414.73K |
| Market Capitalization | $8.87 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values IZOTROPIC CORP.'s assets at a significant premium (21.39x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: IZOTROPIC CORP.'s assets grew by 78.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for IZOTROPIC CORP. (2022–2025)
The table below shows the annual total assets of IZOTROPIC CORP. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | €414.73K ≈ $484.86K |
+78.47% |
| 2024-04-30 | €232.38K ≈ $271.67K |
-47.44% |
| 2023-04-30 | €442.11K ≈ $516.88K |
-80.52% |
| 2022-04-30 | €2.27 Million ≈ $2.65 Million |
-- |
About IZOTROPIC CORP.
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. The company develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses offering high resolution, true 3D dedicated breast imaging with 360-degree image acquisition and can be used with or without injectable contrast. Izotropic Corporation … Read more